124 assets in Leukemia

Therapeutic assets addressing Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Leukemia	National Cancer Institute (NCI)	P4	BB (71)
Vincristine Sulfate Leukemia	Inhye Ahn	P3	BB (71)
Busulfanum Leukemia	National Cancer Institute (NCI)	P4	BB (70)
Daunomycin Leukemia	Richard Stone, MD	P3	BB (70)
Idarubicin Leukemia	Affiliated Hospital of Nantong University	P3	BB (70)
Mercaptopurine Anhydrous Leukemia	Dana-Farber Cancer Institute	P3	BB (70)
Nivestim Leukemia	Hospital General de Mexico	P4	BB (70)
Pegaspargase Leukemia	Dana-Farber Cancer Institute	P3	BB (70)
Adriamycin Leukemia	Dana-Farber Cancer Institute	P3	BB (69)
Etoposide Leukemia	Memorial Sloan Kettering Cancer Center	P3	BB (69)
Methotrexate Leukemia	Dana-Farber Cancer Institute	P3	BB (69)
Prednisone Leukemia	Inhye Ahn	P3	BB (69)
Cytarabine Leukemia	Dana-Farber Cancer Institute	P3	BB (68)
Dexasone Leukemia	Dana-Farber Cancer Institute	P3	BB (68)
Mitoxantrone Leukemia	University of Colorado, Denver	P3	BB (68)
Cyclosporin A Leukemia	Memorial Sloan Kettering Cancer Center	P4	BB (67)
Fludarabine Leukemia	National Cancer Institute (NCI)	P3	BB (67)
Isocyclophosphamide Leukemia	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	P3	BB (67)
Romidepsin Leukemia	National Cancer Institute (NCI)	P3	BB (67)
(+)-Vincristine Leukemia	Dana-Farber Cancer Institute	P2/3	BB (67)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Leukemia	Peking University First Hospital	P4	BB (66)
Melphalan Leukemia	Shanghai Jiao Tong University School of Medicine	P3	BB (66)
Rituximab Leukemia	University of Chicago	P3	BB (66)
Thiotepa Leukemia	Memorial Sloan Kettering Cancer Center	P4	BB (66)
Tretinoin Leukemia	SDK Therapeutics, Inc.	P3	BB (66)
Clofarabine Leukemia	Memorial Sloan Kettering Cancer Center	P3	BB (64)
Arsenic Trioxide Leukemia	SDK Therapeutics, Inc.	P3	B (63)
Azacitidine Leukemia	Jacqueline Garcia, MD	P3	B (63)
Equine Atg Leukemia	Peking University People's Hospital	P2/3	B (63)
Tacrolimus Leukemia	National Cancer Institute (NCI)	P3	B (63)
Allopurinol Leukemia	M.D. Anderson Cancer Center	P2	B (62)
Cladribine Leukemia	M.D. Anderson Cancer Center	P2	B (62)
Decitabine Leukemia	Dana-Farber Cancer Institute	P2/3	B (62)
Lenalidomide Leukemia	M.D. Anderson Cancer Center	P2	B (62)
Sirolimus Leukemia	Masonic Cancer Center, University of Minnesota	P2	B (62)
Quizartinib Leukemia	Daiichi Sankyo	P3	B (60)
Venetoclax Leukemia	Jacqueline Garcia, MD	P3	B (60)
Ibrutinib Leukemia	Inhye Ahn	P2	B (58)
Midostaurin Leukemia	Richard Stone, MD	P3	B (58)
Nelarabine Leukemia	University of Chicago	P2	B (58)
Palifermin Leukemia	Memorial Sloan Kettering Cancer Center	P3	B (57)
Gm-Csf Leukemia	Medical College of Wisconsin	P2	B (56)
Human Immunoglobulins Leukemia	Monash University	P2/3	B (56)
Obinutuzumab Leukemia	Molecular Partners AG	P2	B (56)
Vinorelbine Ditartrate Leukemia	Memorial Sloan Kettering Cancer Center	P1/2	CCC (55)
Hpc, Cord Blood Leukemia	Memorial Sloan Kettering Cancer Center	P2	CCC (54)
Tucidinostat Leukemia	The First Affiliated Hospital of Xiamen University	P2/3	CCC (54)
Vah Leukemia	Ruijin Hospital	P2	CCC (53)
Blinatumomab Leukemia	Dana-Farber Cancer Institute	P2	CCC (52)
Pirtobrutinib Leukemia	Inhye Ahn	P2	CCC (52)

Showing 1 to 50 of 124 assets

PreviousPage 1 of 3Next